Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18164870 | 0.79 | PTPN7 (0.32) | PTPN7DUSP3PTPN12PTPN22 | |
| SCHEMBL18164868 | 0.79 | CA12 (0.32) | ALDH1A1CYP1A2GAAHPGDCYP2C19 | |
| SCHEMBL18164700 | 0.79 | LMNA (0.32) | LMNAL3MBTL1ALDH1A1CYP1A2GAA | |
| SCHEMBL18164785 | 0.79 | NPC1 (0.32) | LMNAL3MBTL1ALDH1A1CYP1A2GAA | |
| SCHEMBL20109614 | 0.79 | MAOA (0.32) | ALDH1A1CYP1A2HPGDCYP2C19SMN1; SMN2 | |
| SCHEMBL18164861 | 0.79 | KMT2A (0.34) | LMNAL3MBTL1ALDH1A1CYP1A2GAA | |
| SCHEMBL24154041 | 0.78 | MAPT (0.37) | LMNAL3MBTL1PTPN7DUSP3PTPN12 | |
| SCHEMBL18164869 | 0.77 | KEAP1 (0.32) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24154581 | 0.77 | MAPT (0.36) | LMNAL3MBTL1PTPN7DUSP3PTPN12 | |
| SCHEMBL18164817 | 0.77 | CA1 (0.31) | LMNAL3MBTL1PTPN7DUSP3PTPN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180123048-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2018-05-03 | — | — | US | disclosed |
| WO-2016167491-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC APPARATUS | 덕산네오룩스 주식회사 | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180123048-A1 | COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT COMPRISING THE SAME AND ELECTRONIC DEVICE THEREOF | PIEZO1, OCIAD1, LEF1 | LMNA 1473/4885L3MBTL1 1020/4885PTPN7 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.